Sector News

Alexion to create 200 jobs in Dublin expansion

May 12, 2015
Life sciences
Biopharma group Alexion has announced plans for a major expansion of its Irish business.
 
Alexion, which is still building the first page of its planned Dublin base, said it will invest a further € 450 million to extend the facility over the next four years.
 
The expansion will see the US-based specialist in rare and ultra rare diseases construct its first biological manufacturing facility outside the US.
 
The company makes Soliris, one of the world’s most expensive drugs, which is used to treat two rare blood conditions.
 
The drug, which costs in the region of € 430,000 per patient per year, received approval for use in Ireland earlier this year after a protracted negotiation.
 
Alexion expects to create 200 jobs with the investment, nearly doubling the numbers employed in Ireland by the company since its arrival here in 2013.
 
Alexion’s Irish executive VP for global operations Julie O’Neill said the project “further underscores our commitment to Ireland and is enabled by our ability to recruit highly competent and professional personnel”.
 
Tanaiste Joan Burton welcomed the announcement and said the company brought the “miracle of hope to parents of children who have life limiting and life threatening conditions”.
 
Also speaking at the announcement, Minister for Enterprise Richard Bruton characterised Alexion as a “wonderful company” whose founders “have fantastic passion”.
 
By Dominic Coyle
 
Source: Irish Times

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

How can we help you?

We're easy to reach